Nuvation Bio
27 articles with Nuvation Bio
-
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/15/2023
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
-
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
12/19/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed the first patient in a Phase 1b study of its BD2-selective BET inhibitor, NUV-868, in combination with olaparib.
-
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
11/3/2022
Nuvation Bio Inc. today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.
-
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2022, and provided a business update.
-
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
8/1/2022
Nuvation Bio Inc. today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422.
-
The decision comes after the FDA put NUV-422, its candidate for high-grade gliomas, on a partial clinical hold, citing safety concerns.
-
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
7/18/2022
Nuvation Bio Inc. today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer.
-
Monday morning, Nuvation Bio announced that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I dose escalation study of NUV-422.
-
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
6/27/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer.
-
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
5/9/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.
-
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/28/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors
1/20/2022
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-868.
-
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones
1/10/2022
Nuvation Bio Inc. provided a corporate update and highlighted key 2022 milestones in anticipation of its presentation at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10 – 13, 2022.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme
12/15/2021
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of patients with high-grade gliomas, including glioblastoma multiforme.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
12/13/2021
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of prostate cancer.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
12/8/2021
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-422, a yclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of advanced breast cancer.
-
Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
11/10/2021
Nuvation Bio Inc. today reported financial results for the third quarter ended September 30, 2021, and provided a business update.
-
Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, reported financial results for the second quarter ended June 30, 2021, and provided a business update.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.